{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T21:45:53Z","timestamp":1782769553206,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008868","name":"Jiangsu Province Department of Science and Technology","doi-asserted-by":"publisher","award":["BK20220099"],"award-info":[{"award-number":["BK20220099"]}],"id":[{"id":"10.13039\/501100008868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008868","name":"Jiangsu Province Department of Science and Technology","doi-asserted-by":"publisher","award":["BE2023731"],"award-info":[{"award-number":["BE2023731"]}],"id":[{"id":"10.13039\/501100008868","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005229","name":"Key Science and Technology Foundation of Gansu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005229","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22307137"],"award-info":[{"award-number":["22307137"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22177129"],"award-info":[{"award-number":["22177129"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.ijbiomac.2024.135456","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T17:10:44Z","timestamp":1725729044000},"page":"135456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P4","title":["Selection of trophoblast cell surface antigen 2-targeted aptamer for the development of cytotoxic aptamer-drug conjugate"],"prefix":"10.1016","volume":"279","author":[{"given":"Wenjing","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjun","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ijbiomac.2024.135456_bb0005","first-page":"1782","article-title":"TROP2 promotes cell proliferation and migration in osteosarcoma through PI3K\/AKT signaling","volume":"18","author":"Gu","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.135456_bb0010","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1476-4598-9-253","article-title":"Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway","volume":"9","author":"Cubas","year":"2010","journal-title":"Mol. Cancer"},{"issue":"5","key":"10.1016\/j.ijbiomac.2024.135456_bb0015","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/ijc.28451","article-title":"A novel human fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo","volume":"134","author":"Lin","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"24","key":"10.1016\/j.ijbiomac.2024.135456_bb0020","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.2016.72.1894","article-title":"Therapy of advanced non-small-cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan","volume":"35","author":"Heist","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2024.135456_bb0025","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-05-1961","article-title":"Clinical significance of TROP2 expression in colorectal cancer","volume":"12","author":"Ohmachi","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"52","key":"10.1016\/j.ijbiomac.2024.135456_bb0030","doi-asserted-by":"crossref","first-page":"20882","DOI":"10.1073\/pnas.0811411106","article-title":"Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics","volume":"105","author":"Goldstein","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.135456_bb0035","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/jcp.2008.060590","article-title":"TROP2 expression as prognostic marker for gastric carcinoma","volume":"62","author":"M\u00fchlmann1","year":"2009","journal-title":"J. Clin. Pathol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2024.135456_bb0040","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/onc.2012.151","article-title":"S, Alberti, the Trop-2 signalling network in cancer growth","volume":"32","author":"Guerra","year":"2013","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.ijbiomac.2024.135456_bb0045","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/sj.bjc.6604677","article-title":"High expression of TROP2 correlates with poor prognosis in pancreatic cancer","volume":"99","author":"Fong","year":"2008","journal-title":"Brit. J. Cancer"},{"issue":"2","key":"10.1016\/j.ijbiomac.2024.135456_bb0050","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/iep.12174","article-title":"Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma","volume":"97","author":"Xu","year":"2016","journal-title":"Int. J. Exp. Pathol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.135456_bb0055","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1159\/000522206","article-title":"Trophoblast cell surface antigen 2 expression in human tumors: a tissue microarray study on 18,563 tumors","volume":"89","author":"Dum","year":"2022","journal-title":"Pathobiology"},{"issue":"24","key":"10.1016\/j.ijbiomac.2024.135456_bb0060","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.21037\/atm-22-5976","article-title":"A literature review of the promising future of TROP2: a potential drug therapy target","volume":"10","author":"Wen","year":"2022","journal-title":"Ann. Transl. Med."},{"issue":"10","key":"10.1016\/j.ijbiomac.2024.135456_bb0065","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3390\/vaccines9101111","article-title":"Antibody-drug conjugates: functional principles and applications in oncology and beyond","volume":"9","author":"Theocharopoulos","year":"2021","journal-title":"Vaccines"},{"issue":"10","key":"10.1016\/j.ijbiomac.2024.135456_bb0070","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-10-2939","article-title":"Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys","volume":"17","author":"Cardillo","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.ijbiomac.2024.135456_bb0075","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/14728222.2022.2113513","article-title":"TROP2 (trophoblast cell-surface antigen 2): a drug target for breast cancer","volume":"26","author":"Cortesi","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.135456_bb0080","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/2159-8290.CD-22-1368","article-title":"Antibody-exatecan conjugates with a novel self-immolative moiety overcome resistance in colon and lung cancer","volume":"13","author":"Weng","year":"2003","journal-title":"Cancer Discov."},{"issue":"18","key":"10.1016\/j.ijbiomac.2024.135456_bb0085","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1073\/pnas.1717705115","article-title":"Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer","volume":"115","author":"Powell Gray","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.ijbiomac.2024.135456_bb0090","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.bioeng.2007.06.001","article-title":"SELEX-A (r)evolutionary method to generate high-affinity nucleic acid ligands","volume":"24","author":"Stoltenburg","year":"2007","journal-title":"Biomol. Eng."},{"issue":"12","key":"10.1016\/j.ijbiomac.2024.135456_bb0095","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1002\/bit.26389","article-title":"Development of aptamers against unpurified proteins","volume":"114","author":"Goto","year":"2017","journal-title":"Biotechnol. Bioeng."},{"issue":"6","key":"10.1016\/j.ijbiomac.2024.135456_bb0100","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3390\/pharmaceutics13060888","article-title":"Hybrid-type SELEX for the selection of artificial nucleic acid aptamers exhibiting cell internalization activity","volume":"13","author":"Uemachi","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijbiomac.2024.135456_bb0105","doi-asserted-by":"crossref","first-page":"1053984","DOI":"10.3389\/fcell.2022.1053984","article-title":"Aptamer nucleotide analog drug conjugates in the targeting therapy of cancers","volume":"10","author":"Li","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ijbiomac.2024.135456_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.972933","article-title":"Recent advances in aptamer-based targeted drug delivery systems for cancer therapy","volume":"10","author":"Gao","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.135456_bb0115","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/GCO.0000000000000830","article-title":"New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023","volume":"35","author":"Banys-Paluchowski","year":"2023","journal-title":"Curr. Opin. Obstet. Gynecol."},{"issue":"22","key":"10.1016\/j.ijbiomac.2024.135456_bb0120","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Lewis Phillips","year":"2008","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/j.ijbiomac.2024.135456_bb0125","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1158\/1078-0432.CCR-14-0012","article-title":"FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer","volume":"20","author":"Amiri-Kordestani","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.135456_bb0130","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"issue":"32","key":"10.1016\/j.ijbiomac.2024.135456_bb0135","doi-asserted-by":"crossref","first-page":"11838","DOI":"10.1073\/pnas.0602615103","article-title":"Aptamers evolved from live cells as effective molecular probes for cancer study","volume":"103","author":"Shangguan","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"13","key":"10.1016\/j.ijbiomac.2024.135456_bb0140","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1093\/nar\/gkg595","article-title":"Mfold web server for nucleic acid folding and hybridization prediction","volume":"31","author":"Zuker","year":"2003","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2024.135456_bb0145","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/GCO.0000000000000515","article-title":"Antibody-drug conjugates for ovarian cancer: current clinical development","volume":"31","author":"Stewart","year":"2019","journal-title":"Curr. Opin. Obstet. Gynecol."},{"issue":"19","key":"10.1016\/j.ijbiomac.2024.135456_bb0150","doi-asserted-by":"crossref","first-page":"12133","DOI":"10.1021\/acs.chemrev.7b00013","article-title":"Ligand-targeted drug delivery","volume":"117","author":"Srinivasarao","year":"2017","journal-title":"Chem. Rev."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024062640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813024062640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T21:10:21Z","timestamp":1782767421000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813024062640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":30,"alternative-id":["S0141813024062640"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.135456","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selection of trophoblast cell surface antigen 2-targeted aptamer for the development of cytotoxic aptamer-drug conjugate","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2024.135456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"135456"}}